** Shares of Cambium Bio CMB.AX up as much as 30.2% to A$0.28, hitting highest level since April 24
** Regenerative medicine maker says it cleared US FDA's regulatory requirements to initiate patient dosing in its Phase 3 clinical trials of Elate Ocular which can be used to treat dry eye disease
** About 93,600 shares change hands, 18x the 30-day average
** Stock down 30% YTD, at current levels
(Reporting by Anjali Singh in Bengaluru)
((anjali.singh2@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。